- Home
- NXL vs TLPH Comparison
NXL vs TLPH Comparison
Compare NXL & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXL
- TLPH
- Stock Information
- Founded
- NXL 2010
- TLPH 2005
- Country
- NXL United States
- TLPH United States
- Employees
- NXL N/A
- TLPH N/A
- Industry
- NXL Medical Specialities
- TLPH Biotechnology: Pharmaceutical Preparations
- Sector
- NXL Health Care
- TLPH Health Care
- Exchange
- NXL Nasdaq
- TLPH Nasdaq
- Market Cap
- NXL 10.0M
- TLPH 17.7M
- IPO Year
- NXL 2022
- TLPH 2011
- Fundamental
- Price
- NXL $0.83
- TLPH $0.99
- Analyst Decision
- NXL
- TLPH Strong Buy
- Analyst Count
- NXL 0
- TLPH 2
- Target Price
- NXL N/A
- TLPH $4.50
- AVG Volume (30 Days)
- NXL 158.7K
- TLPH 73.6K
- Earning Date
- NXL 09-17-2024
- TLPH 08-14-2024
- Dividend Yield
- NXL N/A
- TLPH N/A
- EPS Growth
- NXL N/A
- TLPH N/A
- EPS
- NXL N/A
- TLPH N/A
- Revenue
- NXL $150,159.00
- TLPH $398,000.00
- Revenue This Year
- NXL N/A
- TLPH N/A
- Revenue Next Year
- NXL N/A
- TLPH N/A
- P/E Ratio
- NXL N/A
- TLPH N/A
- Revenue Growth
- NXL N/A
- TLPH 57.31
- 52 Week Low
- NXL $0.25
- TLPH $0.43
- 52 Week High
- NXL $4.05
- TLPH $1.61
- Technical
- Relative Strength Index (RSI)
- NXL 34.06
- TLPH 54.80
- Support Level
- NXL $0.90
- TLPH $0.92
- Resistance Level
- NXL $1.05
- TLPH $1.05
- Average True Range (ATR)
- NXL 0.08
- TLPH 0.08
- MACD
- NXL 0.00
- TLPH 0.01
- Stochastic Oscillator
- NXL 19.66
- TLPH 59.09
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.